Targeting the processes that help pancreatic cancer grow and spread
Targeting ribosome biogenesis and desmoplastic tumor microenvironment for the treatment of advanced pancreatic cancer
This study is looking to create a new treatment for advanced pancreatic cancer that could help make existing therapies work better by targeting important factors that help the cancer grow and make it hard for medicines to reach the tumor, so patients might have more effective options to fight their cancer.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Texas Rio Grande Valley NIH-funded |
| Lab location | 1 site (Edinburg, United States) |
| Project ID | NIH-10818596 on NIH RePORTER |
What this research studies
This research focuses on improving treatment options for advanced pancreatic cancer, which is notoriously difficult to treat. It aims to develop a new therapy that targets two key factors contributing to the disease: ribosome biogenesis, which is crucial for cancer cell growth, and the desmoplastic tumor microenvironment that hinders drug delivery. By using specific inhibitors, the research seeks to enhance the effectiveness of existing treatments and overcome resistance to chemotherapy. Patients may benefit from a more effective treatment regimen that addresses the unique challenges posed by pancreatic cancer.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with advanced pancreatic cancer who have not responded well to standard therapies.
Not a fit: Patients with early-stage pancreatic cancer or those who have not been diagnosed with pancreatic cancer may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for patients with advanced pancreatic cancer.
How similar studies have performed: While targeting ribosome biogenesis and the tumor microenvironment is a novel approach, similar strategies have shown promise in other cancer types, indicating potential for success.
Where this research is happening
Edinburg, United States
- University of Texas Rio Grande Valley — Edinburg, United States (Active)
Researchers
- Principal investigator: Hafeez, Bilal Bin — University of Texas Rio Grande Valley
- Study coordinator: Hafeez, Bilal Bin
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.